Week of March 28, 2022 | Vol. 11, Issue 13
|
|
|
In This Issue
Upcoming Events
Industry M&A Activity
Recent Transactions
Trading Comps
Market Reports
M&A Pipeline
Featured Headlines
Tanner Updates
Quick Links
Contact Information
Managing Director
Business Development
Managing Director
Head of M&A and Capital Advisory
|
|
Above is an overview of recent industry M&A activity. Click on the chart to download complete transaction tables broken out by industry sub sectors. For additional information, see the Industry M&A Activity section below.
|
|
Events Hosted or Attended by Bourne Partners
|
|
|
May 17-19, 2022 - Philadelphia, PA
|
|
|
May 24-26, 2022 - New York City, NY
|
|
|
April 23-26, 2022 - Palm Beach, FL
|
|
|
June 13-16, 2022 - San Diego, CA
|
|
|
October 2022 - Charlotte, NC
|
|
INDUSTRY M&A ACTIVITY
Recent Transactions, Trading Comps, Market Reports, M&A Pipeline
|
|
RECENT TRANSACTIONS
An Overview of Transactions Within Market Sub-segments
|
|
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
|
|
|
Pharma & Biotech
9 transactions totaling $1,622 million
Supplies, Equipment & Services
19 transactions totaling $10 million
Healthcare IT & Managed Care
3 transactions
Healthcare Facilities & Distributors
11 transactions totaling $1,387 million
|
|
|
Pharma & Biotech
38 transactions totaling $778 million
Supplies, Equipment & Services
35 transactions totaling $490 million
Healthcare IT & Managed Care
15 transactions totaling $270 million
Healthcare Facilities & Distributors
1 transaction
|
|
|
Pharma & Biotech
15 transactions totaling $1,342 million
Supplies, Equipment & Services
3 transactions totaling $45 million
Healthcare IT & Managed Care
3 transactions totaling $800 million
Healthcare Facilities & Distributors
1 transaction totaling $28 million
|
|
TRADING COMPS
A Breakdown of Relevant Trading Multiples
|
|
|
This is a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.
For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table.
Note: data reflects prior week close.
|
|
MARKET REPORTS
Insight Into Healthcare Related Industries
|
|
M&A PIPELINE
Representative Current Retained Sell-Side And Partnering Opportunities
|
|
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America
Project Nucleus
Buy-side| CDMO | North American radiopharmaceutical company
|
|
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products
Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
|
|
FEATURED HEADLINES
A Sampling of Industry Headlines From Last Week
|
|
Tanner Pharma Group, an international distributor of essential medicines, announced that it has significantly increased its inventory of Leukine (sargramostim, yeast-derived rhuGM-CSF) to be held in Europe. This action is being taken in partnership with Leukine’s owner, Partner Therapeutics (PTx), in response to the ongoing war in Ukraine and escalating potential for incidents that could require rapid deployment of medical interventions to treat radiation or chemical exposure.
“In response to the ongoing conflict in Ukraine, Tanner is supporting preparedness and response in Europe by increasing the local inventory of Leukine that can be rapidly deployed in response to an emergency,” said Banks Bourne, CEO and Founder of Tanner Pharma. “The unique efficacy of Leukine, which has been shown to improve survival when given within 96 hours after radiation exposure and without whole blood transfusions, makes it a highly effective countermeasure with important logistical advantages in the event of a nuclear detonation. Positioning more supply in Europe ensures that more Leukine is available quickly, if needed.”
|
|
March 21, 2022 - Fierce Biotech
|
Ever since last year's annual American Association of Cancer Research (AACR) meeting, Volastra's phone has been "ringing off the hook," according to CEO Charles Hugh-Jones, M.D.
|
|
March 21, 2022 - Fierce Healthcare
|
Three big players in kidney care—Fresenius Health Partners, Cricket Health, and InterWell Health—plan to form a new value-based care company focused on services for the earlier stages of kidney disease.
|
|
March 22, 2022- Fierce Healthcare
|
A new study found that over the last decade, rural counties that had a hospital shut its doors had a higher share of Black and Hispanic residents and greater shares of income inequality compared to prior decades.
|
|
March 23, 2022- Fierce Biotech
|
With a new CEO and a phase 2 trial ready to go, Ocelot Bio has snagged $36 million in a series A financing led by RA Capital Management, Venrock and Vivo Capital.
|
|
The work of TannerGAP includes addressing medicine market withdrawal, post-clinical trial solutions, mitigating drug shortages and managing medicine supply on a Named Patient basis. Learn more from TannerGAP EVP, Maryori Alvarenga.
|
|
When demand for PPE and testing kits surged to unparalleled levels in March 2020 during the first wave of Covid-19, Tanner had to do something to help. Learn more about the development of TannerGMS (global medical supplies) and the future of medical supplies and diagnostics here.
|
|
The Tanner team will be attending several networking events in the coming weeks. Let’s connect to discuss how our organizations can improve patient lives, together.
|
|
|
|
|
|
|